Foretinib

Foretinib

Names
IUPAC name N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-quinolyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Other names XL880; EXEL-2880; GSK1363089; GSK089
Identifiers
CAS Number	849217-64-7
ChEMBL	ChEMBL1908393
ChemSpider	24608641
Jmol interactive 3D	Image
UNII	81FH7VK1C4
InChI InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
SMILES COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
Properties
Chemical formula	C34H34F2N4O6
Molar mass	632.66 g·mol^−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Foretinib is an experimental drug candidate for the treatment of cancer.^[1] It was discovered by Exelixis and is under development by GlaxoSmithKline.^[2] About 10 Phase II clinical trials have been run.^[3] As of October 2015 no phase III trials are registered.^[3]

Foretinib is an inhibitor of the kinase enzymes c-Met and vascular endothelial growth factor receptor 2 (VEGFR-2).^[4]

See also

• c-Met inhibitors
• Cabozantinib, a similar molecule and kinase inhibitor with FDA approval
• VEGFR inhibitor
• tyrosine-kinase inhibitor

References

1. Hedgethorne, K., Huang, P.H. (2010). "Foretinib. c-Met and VEGFR-2 inhibitor, Oncolytic". Drugs Fut 35 (11): 893–901. doi:10.1358/dof.2010.35.11.1529012 (inactive 2015-01-13).
2. "XL880 (GSK1363089)". Exelixis, Inc.
3. "Foretinib". clinicaltrials.gov.
4. Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J; et al. (2009). "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases". Cancer Research 69 (20): 8009–16. doi:10.1158/0008-5472.CAN-08-4889. PMID 19808973.